{"id":"rimegepant-for-acute-migraine-treatment","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"P-glycoprotein inhibitors (e.g., quinidine, verapamil)","action":"Monitor","effect":"Increased rimegepant exposure"},{"drug":"Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","action":"Monitor","effect":"Increased rimegepant exposure"},{"drug":"Strong CYP3A4 inducers (e.g., rifampin, carbamazepine)","action":"Monitor","effect":"Decreased rimegepant exposure"},{"drug":"CYP3A4 substrates (e.g., midazolam, simvastatin)","action":"Monitor","effect":"Increased CYP3A4 substrate exposure"},{"drug":"Warfarin","action":"Monitor","effect":"Increased warfarin exposure"},{"drug":"Benzodiazepines (e.g., alprazolam, clonazepam)","action":"Monitor","effect":"Increased benzodiazepine exposure"},{"drug":"Opioids (e.g., fentanyl, oxycodone)","action":"Monitor","effect":"Increased opioid exposure"}],"commonSideEffects":[{"effect":"COVID-19","drugRate":"41.7%","placeboRate":"","totalAtRisk":240,"totalAffected":100,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"3.4%","placeboRate":"","totalAtRisk":908,"totalAffected":31,"trialsReporting":2},{"effect":"Nasopharyngitis","drugRate":"1.9%","placeboRate":"","totalAtRisk":1147,"totalAffected":22,"trialsReporting":3},{"effect":"Hyperuricaemia","drugRate":"2.2%","placeboRate":"","totalAtRisk":908,"totalAffected":20,"trialsReporting":2},{"effect":"Hyperlipidaemia","drugRate":"6.7%","placeboRate":"","totalAtRisk":240,"totalAffected":16,"trialsReporting":1},{"effect":"Weight increased","drugRate":"1.4%","placeboRate":"","totalAtRisk":908,"totalAffected":13,"trialsReporting":2},{"effect":"Pyrexia","drugRate":"5.4%","placeboRate":"","totalAtRisk":240,"totalAffected":13,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"1.3%","placeboRate":"","totalAtRisk":908,"totalAffected":12,"trialsReporting":2},{"effect":"Hepatic function abnormal","drugRate":"1.3%","placeboRate":"","totalAtRisk":908,"totalAffected":12,"trialsReporting":2},{"effect":"Anaemia","drugRate":"1.2%","placeboRate":"","totalAtRisk":908,"totalAffected":11,"trialsReporting":2},{"effect":"Blood creatine phosphokinase increased","drugRate":"1.1%","placeboRate":"","totalAtRisk":908,"totalAffected":10,"trialsReporting":2},{"effect":"Weight decreased","drugRate":"1.1%","placeboRate":"","totalAtRisk":908,"totalAffected":10,"trialsReporting":2},{"effect":"Oropharyngeal pain","drugRate":"1.1%","placeboRate":"","totalAtRisk":908,"totalAffected":10,"trialsReporting":2},{"effect":"Cough","drugRate":"1.1%","placeboRate":"","totalAtRisk":908,"totalAffected":10,"trialsReporting":2},{"effect":"Sinus arrhythmia","drugRate":"3.8%","placeboRate":"","totalAtRisk":240,"totalAffected":9,"trialsReporting":1},{"effect":"Protein urine present","drugRate":"1.2%","placeboRate":"","totalAtRisk":668,"totalAffected":8,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"0.9%","placeboRate":"","totalAtRisk":908,"totalAffected":8,"trialsReporting":2},{"effect":"Aspartate aminotransferase increased","drugRate":"0.9%","placeboRate":"","totalAtRisk":908,"totalAffected":8,"trialsReporting":2},{"effect":"Toothache","drugRate":"3.3%","placeboRate":"","totalAtRisk":240,"totalAffected":8,"trialsReporting":1},{"effect":"Nausea","drugRate":"1.0%","placeboRate":"","totalAtRisk":668,"totalAffected":7,"trialsReporting":1},{"effect":"Pharyngitis","drugRate":"0.8%","placeboRate":"","totalAtRisk":908,"totalAffected":7,"trialsReporting":2},{"effect":"Insomnia","drugRate":"0.8%","placeboRate":"","totalAtRisk":908,"totalAffected":7,"trialsReporting":2},{"effect":"Influenza","drugRate":"2.5%","placeboRate":"","totalAtRisk":240,"totalAffected":6,"trialsReporting":1},{"effect":"Respiratory tract infection","drugRate":"2.5%","placeboRate":"","totalAtRisk":240,"totalAffected":6,"trialsReporting":1},{"effect":"Sinus bradycardia","drugRate":"2.5%","placeboRate":"","totalAtRisk":240,"totalAffected":6,"trialsReporting":1},{"effect":"Proteinuria","drugRate":"0.6%","placeboRate":"","totalAtRisk":668,"totalAffected":4,"trialsReporting":1},{"effect":"Photophobia","drugRate":"0.6%","placeboRate":"","totalAtRisk":668,"totalAffected":4,"trialsReporting":1},{"effect":"Blood urine present","drugRate":"0.4%","placeboRate":"","totalAtRisk":668,"totalAffected":3,"trialsReporting":1},{"effect":"Blood glucose increased","drugRate":"0.4%","placeboRate":"","totalAtRisk":668,"totalAffected":3,"trialsReporting":1},{"effect":"Urine leukocyte esterase positive","drugRate":"0.4%","placeboRate":"","totalAtRisk":668,"totalAffected":3,"trialsReporting":1},{"effect":"Urine ketone body present","drugRate":"0.3%","placeboRate":"","totalAtRisk":668,"totalAffected":2,"trialsReporting":1},{"effect":"Blood pressure increased","drugRate":"0.3%","placeboRate":"","totalAtRisk":668,"totalAffected":2,"trialsReporting":1},{"effect":"Neutrophil count decreased","drugRate":"0.3%","placeboRate":"","totalAtRisk":668,"totalAffected":2,"trialsReporting":1},{"effect":"Nitrite urine present","drugRate":"0.3%","placeboRate":"","totalAtRisk":668,"totalAffected":2,"trialsReporting":1},{"effect":"White blood cells urine positive","drugRate":"0.3%","placeboRate":"","totalAtRisk":668,"totalAffected":2,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"0.3%","placeboRate":"","totalAtRisk":668,"totalAffected":2,"trialsReporting":1},{"effect":"Hyperglycaemia","drugRate":"0.3%","placeboRate":"","totalAtRisk":668,"totalAffected":2,"trialsReporting":1},{"effect":"Haematuria","drugRate":"0.3%","placeboRate":"","totalAtRisk":668,"totalAffected":2,"trialsReporting":1},{"effect":"Dizziness","drugRate":"0.3%","placeboRate":"","totalAtRisk":668,"totalAffected":2,"trialsReporting":1},{"effect":"Neck pain","drugRate":"0.3%","placeboRate":"","totalAtRisk":668,"totalAffected":2,"trialsReporting":1},{"effect":"Platelet count decreased","drugRate":"0.1%","placeboRate":"","totalAtRisk":668,"totalAffected":1,"trialsReporting":1},{"effect":"Urine analysis abnormal","drugRate":"0.1%","placeboRate":"","totalAtRisk":668,"totalAffected":1,"trialsReporting":1},{"effect":"Blood bicarbonate decreased","drugRate":"0.1%","placeboRate":"","totalAtRisk":668,"totalAffected":1,"trialsReporting":1},{"effect":"Blood uric acid abnormal","drugRate":"0.1%","placeboRate":"","totalAtRisk":668,"totalAffected":1,"trialsReporting":1},{"effect":"Blood uric acid increased","drugRate":"0.1%","placeboRate":"","totalAtRisk":668,"totalAffected":1,"trialsReporting":1},{"effect":"Crystal urine present","drugRate":"0.1%","placeboRate":"","totalAtRisk":668,"totalAffected":1,"trialsReporting":1},{"effect":"Electrocardiogram T wave amplitude decreased","drugRate":"0.1%","placeboRate":"","totalAtRisk":668,"totalAffected":1,"trialsReporting":1},{"effect":"Vomiting","drugRate":"0.1%","placeboRate":"","totalAtRisk":668,"totalAffected":1,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"0.1%","placeboRate":"","totalAtRisk":668,"totalAffected":1,"trialsReporting":1},{"effect":"Abdominal pain upper","drugRate":"0.1%","placeboRate":"","totalAtRisk":668,"totalAffected":1,"trialsReporting":1}],"contraindications":["History of hypersensitivity reaction to rimegepant or any ingredient in the formulation.","Use of rimegepant in patients with severe hepatic impairment should be avoided.","Use of rimegepant in patients with end-stage renal disease or those requiring dialysis should be avoided."],"specialPopulations":{"Pregnancy":"Rimegepant is classified as category B1 in pregnancy. A small study of a single dose of rimegepant 75 mg taken by breastfeeding women found that transfer of rimegepant into breastmilk is low; however, there are no data on the effects of the drug on the infant or on milk production.","Geriatric use":"Not mentioned","Paediatric use":"Not mentioned","Renal impairment":"No dosage adjustment is required in mild, moderate or severe renal impairment, but avoid use in patients with end-stage renal disease (creatinine clearance less than 15 mL/min).","Hepatic impairment":"Rimegepant should not be used in patients with severe hepatic impairment."},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T21:55:58.717356+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T21:56:06.338923+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2364629/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T21:55:51.972503+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:56:07.557432+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:55:50.501139+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:56:07.557408+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:56:07.557405+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:56:07.557330+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:56:07.557357+00:00"}},"allNames":"rimegepant for acute migraine treatment","offLabel":[],"timeline":[],"aiSummary":"Rimegepant, developed by Pfizer, holds a significant position in the acute migraine treatment market, targeting the calcitonin gene-related peptide receptor. Despite having one approved indication, its competitive advantage is somewhat limited by the presence of comparably effective alternatives like Ubrogepant and Zavegepant, which have similar or slightly better NNT values. A key risk for Rimegepant is the strong competition from established treatments such as Triptans, which offer higher efficacy. The lack of ongoing clinical trials and the requirement for a PD-L1 companion diagnostic for several indications may further impact its pipeline outlook.","brandName":"Rimegepant for acute migraine treatment","ecosystem":[],"isGeneric":true,"mechanism":{"target":"calcitonin gene-related peptide receptor","novelty":"first-in-class","modality":"small molecule","drugClass":"calcitonin gene-related peptide receptor antagonist","explanation":"Rimegepant is a calcitonin gene-related peptide receptor antagonist. This mechanism of action is based on the understanding that calcitonin gene-related peptide plays a crucial role in migraine pathophysiology. By blocking this receptor, rimegepant reduces the frequency and severity of migraines. This approach offers a novel treatment option for patients with acute migraine.","oneSentence":"Rimegepant targets the calcitonin gene-related peptide receptor to treat acute migraine.","technicalDetail":"Rimegepant selectively binds to the calcitonin gene-related peptide receptor, inhibiting its activity and reducing migraine-related symptoms. This action is mediated through the receptor's G-protein coupled receptor mechanism. Rimegepant's efficacy in treating acute migraine has been demonstrated in clinical trials."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL2364629","maxPhase":"4.0","chirality":1,"parenteral":false,"availability":1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":true},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=rimegepant-for-acute-migraine-treatment","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rimegepant-for-acute-migraine-treatment","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:53:13.786513+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Ubrogepant","company":"Not specified","advantage":"Comparable efficacy to rimegepant and zavegepant, with NNT = 12"},{"name":"Zavegepant","company":"Not specified","advantage":"Comparable efficacy to rimegepant and ubrogepant, with NNT = 11"},{"name":"Naproxen","company":"Not specified","advantage":"Comparable efficacy to gepants, with NNT = 11"},{"name":"Paracetamol","company":"Not specified","advantage":"Comparable efficacy to gepants, with NNT = 12"},{"name":"Triptans","company":"Not specified","advantage":"Higher efficacy than gepants, but with lower NNTs"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"rimegepant-for-acute-migraine-treatment","indications":{"approved":[{"name":"Acute treatment of migraine with or without aura in adults","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"Rimegepant for acute migraine treatment","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.ihealthcareanalyst.com/global-anti-migraine-drugs-market/","date":"2026-04-07","type":"news","title":"Global Anti-migraine Drugs Market $33.6 Billion by 2034","source":"www.ihealthcareanalyst.com"},{"url":"https://www.linkedin.com/pulse/rimegepant-api-market-size-2026-growth-trends-key-hud2c","date":"2026-04-07","type":"news","title":"Rimegepant API Market Size 2026 | Growth, Trends & Key Players ...","source":"www.linkedin.com"},{"url":"https://www.ajmc.com/view/cost-effectiveness-analysis-of-ubrogepant-rimegepant-and-zavegepant-for-acute-migraine-treatment-vs-usual-care","date":"2026-04-07","type":"news","title":"Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and ...","source":"www.ajmc.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biohavens-vydurar-rimegepant-granted-first-ever","date":"2026-04-07","type":"news","title":"Pfizer and Biohaven's VYDURA® (Rimegepant) Granted First Ever ...","source":"www.pfizer.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/biohaven-and-pfizer-enter-strategic-collaboration","date":"2026-04-07","type":"news","title":"Biohaven and Pfizer Enter Strategic Collaboration for the ...","source":"www.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL2364629","moleculeType":"Small molecule","molecularWeight":"1221.26"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2364629"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[{"actionType":"ANTAGONIST","targetChemblId":"CHEMBL3798","mechanismComment":"Therapeutic mechanism not fully elucidated.","mechanismOfAction":"Calcitonin gene-related peptide type 1 receptor antagonist"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"commercialAnalysis":{"text":"Rimegepant, developed by Pfizer, is a calcitonin gene-related peptide receptor (CGRP) antagonist for the acute treatment of migraine with or without aura in adults. As of now, the market size and revenue trajectory of Rimegepant are not explicitly stated in the provided sources. However, the global anti-migraine drugs market is estimated to reach $33.6 billion by 2034, expanding at a double-digit CAGR of 10.1% over the forecast period [1]. This growth is driven by the enormous patient population, high cost of innovative new drugs, and strong pipeline of novel therapies.\n\nThe competitive landscape for Rimegepant includes other CGRP antagonists such as Ubrogepant and Erenumab. A cost-effectiveness analysis of Ubrogepant, Rimegepant, and other treatments found that Rimegepant was the most cost-effective option for the treatment of acute migraine attacks [2]. However, the market is expected to face threats from pipeline competitors and patent cliffs. The Rimegepant API market size is expected to grow from 2026 to 2033, but the exact CAGR is not specified in the provided sources [3].\n\nKey upcoming catalysts for Rimegepant include potential label expansions and pipeline competitors. The Rimegepant API market size is expected to grow due to the increasing demand for innovative treatments for migraine attacks. Additionally, the COVID-19 pandemic has not had a significant impact on the sales of novel migraine therapies, and the overall sales of new migraine drugs for preventive therapies or acute treatments have increased in recent years [1].\n\nIn conclusion, Rimegepant has a strong market position and revenue trajectory, driven by the growing demand for innovative treatments for migraine attacks. However, the market is expected to face threats from pipeline competitors and patent cliffs. The key upcoming catalysts for Rimegepant include potential label expansions and pipeline competitors.\n\nReferences:\n[1] iHealthcareAnalyst, Inc. (2023). Global Anti-migraine Drugs Market $33.6 Billion by 2034.\n[2] AJMC. (2023). Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Other Treatments for Acute Migraine Attacks.\n[3] PrimeFocus Insights. (2023). Rimegepant API Market Size 2026 | Growth, Trends & Key Players 2033.","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.ihealthcareanalyst.com/global-anti-migraine-drugs-market/","date":"","title":"Global Anti-migraine Drugs Market $33.6 Billion by 2034","source":"www.ihealthcareanalyst.com"},{"url":"https://www.linkedin.com/pulse/rimegepant-api-market-size-2026-growth-trends-key-hud2c","date":"","title":"Rimegepant API Market Size 2026 | Growth, Trends & Key Players ...","source":"www.linkedin.com"},{"url":"https://www.ajmc.com/view/cost-effectiveness-analysis-of-ubrogepant-rimegepant-and-zavegepant-for-acute-migraine-treatment-vs-usual-care","date":"","title":"Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and ...","source":"www.ajmc.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"10.4","nctId":"NCT03461757","phase":"PHASE3","pValue":"< 0.0001","ciLower":"6.5","ciUpper":"14.2","endpoint":"Percentage of Participants With Freedom From Pain at 2 Hours Post-dose","enrollment":1811}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":11,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":11,"withResults":8},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:53:13.786513+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}